Cellebrite Announces First-Quarter 2024 Results
Cellebrite (NASDAQ: CLBT) announced its Q1 2024 results, reporting a 27% year-over-year increase in Annual Recurring Revenue (ARR) to $331.8 million. Q1 2024 revenue rose by 26% to $89.6 million, driven by a 29% growth in subscription revenue. The company recorded a GAAP net loss of $71.4 million and a non-GAAP net income of $16.9 million. Adjusted EBITDA stood at $17.6 million with a 19.7% margin. CEO Yossi Carmil emphasized the global expansion and profitability improvements, noting the positive reception of new products like the Inseyets digital forensics software. The company reaffirmed its outlook for 2024, expecting ARR between $380 million and $400 million, and revenue between $370 million and $380 million for the full year.
- ARR of $331.8 million, up 27% year-over-year.
- Q1 2024 revenue of $89.6 million, up 26% year-over-year.
- Subscription revenue increased by 29% year-over-year.
- Non-GAAP net income of $16.9 million.
- Adjusted EBITDA of $17.6 million with a 19.7% margin.
- Reaffirmed full-year 2024 guidance with ARR expected between $380 million and $400 million.
- Projected full-year revenue between $370 million and $380 million.
- GAAP net loss of $71.4 million.
- GAAP Diluted loss per share of $(0.36).
Insights
Cellebrite's first-quarter 2024 financial results demonstrate impressive growth across several key metrics. Annual Recurring Revenue (ARR) of $331.8 million, reflecting a
However, the GAAP net loss of $(71.4) million stands out as a significant concern. This loss might be attributed to various factors, such as share-based compensation expenses and amortization of acquired intangible assets, which are excluded in non-GAAP measures. Despite this, the non-GAAP net income of $16.9 million provides a more optimistic view of the company's operational performance, excluding one-time costs and non-cash expenses.
In summary, while the strong revenue growth and improving adjusted EBITDA margins are positive indicators, the substantial GAAP net loss warrants close attention. Investors should consider both short-term and long-term implications, balancing strong operational performance with underlying financial challenges.
Cellebrite's advancements in digital forensic capabilities are noteworthy. The launch of Cellebrite Endpoint Inspector SaaS highlights the company's innovative approach to addressing the needs of public sector customers, enterprise customers and eDiscovery service providers. This solution allows for streamlined collection and analysis of data from varied remote devices within a secure, consent-based framework, enhancing the efficiency and reliability of digital investigations.
The company's move to authorize its SaaS offerings with the Federal Risk and Authorization Management Program (FedRAMP®) further reinforces its commitment to security standards and broadens its potential customer base within the federal space. This could lead to faster procurement processes and increased adoption among federal clients, potentially resulting in further revenue growth.
Overall, these technological advancements position Cellebrite well within the digital forensic market, aligning their solutions with evolving customer needs and regulatory requirements, which can drive sustained growth and market leadership in the long term.
Cellebrite's strong market traction is evident from the recurring revenue dollar-based net retention rate of 125%. This metric indicates that existing customers are significantly increasing their spend on Cellebrite's solutions, reflecting high customer satisfaction and value derived from their offerings. The company's emphasis on expanding its global footprint and deepening engagements with existing customers has paid off, contributing to robust ARR and subscription revenue growth.
Moreover, the reaffirmation of the company's full-year 2024 outlook projects confidence in continued growth. The anticipated ARR of $380 million to $400 million, representing an annual growth rate of
In conclusion, Cellebrite's market position remains strong, driven by effective customer retention and strategic expansion efforts. Investors should consider the company's solid growth prospects and ongoing market dynamics, which indicate positive long-term performance potential.
ARR of
Q1 2024 revenue of
Q1 2024 adjusted EBITDA of
TYSONS CORNER, Va. and PETAH TIKVA, Israel, May 23, 2024 (GLOBE NEWSWIRE) -- Cellebrite (NASDAQ: CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, today announced financial results for the three months ending March 31, 2024.
“Cellebrite is off to a very solid start to 2024 as we continued to grow wallet share with existing customers around the world,” said Yossi Carmil, Cellebrite’s CEO. “Our strong first-quarter performance was anchored by the further expansion of our business around the globe, improved profitability versus the same quarter one year ago and meaningful strategic progress. It is exciting to see that our Case-to-Closure platform is resonating in the marketplace, highlighted by increasing traction with our new Inseyets digital forensics software. Looking ahead, we continue to see customer budgets trend favorably in support of their plans to enhance and expand their digital investigative capabilities with our solutions over the coming quarters. We are excited about our prospects over the coming quarters and have reaffirmed our outlook for this year.”
First-Quarter 2024 Financial Highlights
- Annual Recurring Revenue (ARR) of
$331.8 million , up27% year-over-year - Revenue of
$89.6 million , up26% year-over-year - Subscription revenue was
$79.2 million , up29% year-over-year - Recurring revenue dollar-based net retention rate of
125% - GAAP gross profit and gross margin of
$76.3 million and85.2% , respectively; Non-GAAP gross profit and gross profit margin of$76.8 million and85.7% , respectively - GAAP net loss of
$(71.4) million ; Non-GAAP net income of$16.9 million - GAAP Diluted loss per share of
$(0.36) ; Non-GAAP Diluted EPS of$0.08 - Adjusted EBITDA and Adjusted EBITDA margin of
$17.6 million and19.7% , respectively
First-Quarter 2024 and Recent Business & Operational Highlights
Innovation
- On March 7, 2024, Cellebrite announced the launch of the process to authorize its software-as-a-service offerings with the Federal Risk and Authorization Management Program (FedRAMP®). The authorization will enable Cellebrite’s federal customers to leverage their use of the Company’s SaaS solutions, support faster and more cost-effective procurement processes, eliminate duplicative assessment efforts and ensure consistent application of information security standards. FedRAMP authorization ensures a standardized approach to security assessment, authorization and continuous monitoring for cloud products and services. As part of this process, Cellebrite selected cybersecurity services pioneer Coalfire to support the activities required to complete this process, which is planned to be completed within the next twelve months.
- On March 14, 2024, Cellebrite introduced Cellebrite Endpoint Inspector SaaS, which offers public sector customers, enterprise customers and eDiscovery service providers next-generation digital forensic capabilities that enable the streamlined collection and analysis of data from diverse remote devices, all within a unified, consent-based, secure framework.
Team
- On March 25, 2024, Cellebrite announced the appointment of David Gee as Chief Marketing Officer. Mr. Gee, who brings more than 25 years of global sales and marketing expertise to Cellebrite, oversees Cellebrite’s global marketing strategy and execution to help the Company capitalize on the major growth opportunities ahead in the digital investigations marketplace.
Supplemental financial information can be found on the Investor Relations section of our website at https://investors.cellebrite.com/financial-information/quarterly-results.
Financial Outlook
“Cellebrite’s business momentum from the prior year carried into the first quarter of 2024,” stated Dana Gerner, Cellebrite’s CFO. “Our top-line expansion combined with prudent investment in our technology and go-to-market initiatives enabled us to produce another quarter of improved profitability on a year-over-year basis. We expect to drive solid ARR and revenue expansion in the second quarter, which we anticipate will support higher adjusted EBITDA versus the second quarter of 2023. Although it is still early in the year, we believe we are well positioned to achieve our full-year 2024 targets with an expectation that we will deliver the majority of our revenue and adjusted EBITDA in the second half of the year.”
The Company’s current expectations are as follows:
| Second-Quarter 2024 Expectations (as of 5/23/24) | Full-Year 2024 Expectations (unchanged from 2/15/24) | ||
| ARR | |||
| Annual Growth | |||
| Revenue | |||
| Annual Growth | |||
| Adjusted EBITDA | |||
| Adjusted EBITDA margin | |||
First-Quarter 2024 Conference Call Information
Cellebrite will host a live conference call and webcast later this morning to review the Company’s financial results for the first quarter of 2024 and discuss its 2024 outlook. Relevant details include:
| Date: | Thursday, May 23, 2024 |
| Time: | 8:30 a.m. ET |
| Call-In Number: | 203-518-9783 |
| Conference ID: | CLBTQ124 |
| Event URL: | https://investors.cellebrite.com/events/event-details/cellebrite-q1-2024-financial-results-investor-call-webcast |
| Webcast URL: | https://edge.media-server.com/mmc/p/csujxde4 |
In conjunction with the conference call and webcast, historical financial tables and supplemental data will be available on the quarterly results section of Company’s investor relations website at https://investors.cellebrite.com/financial-information/quarterly-results. A transcript of the call will be added to this page along with access to the replay of the call later in the day.
Non-GAAP Financial Information and Key Performance Indicators
This press release includes non-GAAP financial measures. Cellebrite believes that the use of non-GAAP gross profit, non-GAAP net income, non-GAAP operating income and adjusted EBITDA is helpful to investors. These measures, which the Company refers to as our non-GAAP financial measures, are not prepared in accordance with GAAP.
The Company believes that the non-GAAP financial measures provide a more meaningful comparison of its operational performance from period to period and offers investors and management greater visibility into the underlying performance of its business. Mainly:
- Share-based compensation expenses utilize varying available valuation methodologies, subjective assumptions and a variety of equity instruments that can impact a company’s non-cash expense;
- Acquired intangible assets are valued at the time of acquisition and are amortized over an estimated useful life after the acquisition, and acquisition-related expenses are unrelated to current operations and neither are comparable to the prior period nor predictive of future results;
- To the extent that the above adjustments have an effect on tax (income) expense, such an effect is excluded in the non-GAAP adjustment to net income;
- Tax expense, depreciation and amortization expense vary for many reasons that are often unrelated to our underlying performance and make period-to-period comparisons more challenging; and
- Financial instruments are remeasured according to GAAP and vary for many reasons that are often unrelated to the Company’s current operations and affect financial income.
Each of our non-GAAP financial measures is an important tool for financial and operational decision making and for evaluating our own operating results over different periods of time. The non-GAAP financial measures do not represent our financial performance under U.S. GAAP and should not be considered as alternatives to operating income or net income or any other performance measures derived in accordance with GAAP. Non-GAAP measures should not be considered in isolated from, or as an alternative to, financial measures determined in accordance with GAAP. Non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in our industry, as other companies in our industry may calculate non-GAAP financial results differently, particularly related to non-recurring, unusual items. In addition, there are limitations in using non-GAAP financial measures because the non-GAAP financial measures are not prepared in accordance with GAAP, and exclude expenses that may have a material impact on our reported financial results. Further, share-based compensation expense has been, and will continue to be for the foreseeable future, a significant recurring expense in our business and an important part of the compensation provided to our employees. In addition, the amortization of intangible assets is expected recurring expense over the estimated useful life of the underlying intangible asset and acquisition-related expenses will be incurred to the extent acquisitions are made in the future. Furthermore, foreign exchange rates may fluctuate from one period to another, and the Company does not estimate movements in foreign currencies.
A reconciliation of each of these non-GAAP financial measures to their most comparable GAAP measure is set forth in a table included at the end of this press release, which is also available on the quarterly results section of Company’s investor relations website at https://investors.cellebrite.com/financial-information/quarterly-results.
A reconciliation for Adjusted EBITDA referred to in our “Financial Outlook” is not provided because, as a forward-looking statement, such reconciliation is not available without unreasonable effort due to the high variability, complexity, and difficulty of estimating certain items such as charges to share-based compensation expense and currency fluctuations which could have an impact on our consolidated results. The Company believes the information provided is useful to investors because it can be considered in the context of the Company’s historical disclosures of this measure.
Annual recurring revenue (“ARR”) is defined as the annualized value of active term-based subscription license contracts and maintenance contracts related to perpetual licenses in effect at the end of that period. Term-based license contracts and maintenance contracts for perpetual licenses are annualized by multiplying the revenue of the last month of the period by 12. The annualized value of contracts is a legal and contractual determination made by assessing the contractual terms with our customers. The annualized value of maintenance contracts is not determined by reference to historical revenue, deferred revenue or any other GAAP financial measure over any period. ARR is not a forecast of future revenues, which can be impacted by contract start and end dates and renewal rates.
About Cellebrite
Cellebrite’s (Nasdaq: CLBT) mission is to enable its customers to protect and save lives, accelerate justice and preserve privacy in communities around the world. We are a global leader in Digital Investigative solutions for the public and private sectors, empowering organizations in mastering the complexities of legally sanctioned digital investigations by streamlining intelligence processes. Trusted by thousands of leading agencies and companies worldwide, Cellebrite’s Digital Investigation platform and solutions transform how customers collect, review, analyze and manage data in legally sanctioned investigations. To learn more visit us at www.cellebrite.com, https://investors.cellebrite.com, or follow us on Twitter at @Cellebrite.
Caution Regarding Forward Looking Statements
This document includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “will,” “appear,” “approximate,” “foresee,” “might,” “possible,” “potential,” “believe,” “could,” “predict,” “should,” “could,” “continue,” “expect,” “estimate,” “may,” “plan,” “outlook,” “future” and “project” and other similar expressions that predict, project or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include, but are not limited to, the following: estimated financial information for fiscal year 2024 and certain statements related to seeing customer budgets trend favorably in support of their plans to enhance and expand their digital investigative capabilities with our solutions over the coming quarters; we are excited about our prospects over the coming quarters and have reaffirmed our outlook for this year; we expect to drive solid ARR and revenue expansion in the second quarter, which we anticipate will support higher adjusted EBITDA versus the second quarter of 2023; and we believe we are well positioned to achieve our full-year 2024 targets with an expectation that we will deliver the majority of our revenue and adjusted EBITDA in the second half of the year. Such forward-looking statements including those with respect to 2024 second quarter and full year revenue, annual recurring revenue (ARR) and adjusted EBITDA, as well as commentary associated with future performance, strategies, prospects, and other aspects of Cellebrite’s business are based on current expectations that are subject to risks and uncertainties. A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to: Cellebrite’s ability to keep pace with technological advances and evolving industry standards; Cellebrite’s material dependence on the purchase, acceptance and use of its solutions by law enforcement and government agencies; real or perceived errors, failures, defects or bugs in Cellebrite’s solutions; Cellebrite’s failure to maintain the productivity of sales and marketing personnel, including relating to hiring, integrating and retaining personnel; intense competition in all of Cellebrite’s markets; the inadvertent or deliberate misuse of Cellebrite’s solutions; failure to manage its growth effectively; Cellebrite’s ability to introduce new solutions and add-ons; its dependency on its customers renewing their subscriptions; the low volume of business Cellebrite conducts via e-commerce; risks associated with the use of artificial intelligence; the risk of requiring additional capital to support the growth of its business; risks associated with higher costs or unavailability of materials used to create its hardware product components; fluctuations in foreign currency exchange rates; lengthy sales cycle for some of Cellebrite’s solutions; near term declines in new or renewed agreements; risks associated with inability to retain qualified personnel and senior management; the security of Cellebrite’s operations and the integrity of its software solutions; risks associated with the negative publicity related to Cellebrite’s business and use of its products; risks related to Cellebrite’s intellectual property; the regulatory constraints to which Cellebrite is subject; risks associated with Cellebrite’s operations in Israel, including the ongoing Israel-Hamas war and the risk of a greater regional conflict; risks associated with different corporate governance requirements applicable to Israeli companies and risks associated with being a foreign private issuer and an emerging growth company; market volatility in the price of Cellebrite’s shares; changing tax laws and regulations; risks associated with joint ventures, partnerships and strategic initiatives; risks associated with Cellebrite’s significant international operations; risks associated with Cellebrite’s failure to comply with anti-corruption, trade compliance, anti-money-laundering and economic sanctions laws and regulations; risks relating to the adequacy of Cellebrite’s existing systems, processes, policies, procedures, internal controls and personnel for Cellebrite’s current and future operations and reporting needs; and other factors, risks and uncertainties set forth in the section titled “Risk Factors” in Cellebrite’s annual report on Form 20-F filed with the SEC on March 21, 2024 and as amended on April 12, 2024, and in other documents filed by Cellebrite with the U.S. Securities and Exchange Commission (“SEC”), which are available free of charge at www.sec.gov. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made, in this communication or elsewhere. Cellebrite undertakes no obligation to update its forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.
Contacts:
Andrew Kramer
Vice President, Investor Relations
investors@cellebrite.com
+1 973.206.7760
Media
Victor Cooper
Sr. Director of Corporate Communications + Content Operations
Victor.cooper@cellebrite.com
+1 404 804 5910
| Cellebrite DI Ltd. First-Quarter 2024 Results Summary (U.S Dollars in thousands) | |||||||
| For the three months ended | |||||||
| March 31, | |||||||
| 2024 | 2023 | ||||||
| (Unaudited) | (Unaudited) | ||||||
| Revenue | 89,582 | 71,234 | |||||
| Gross profit | 76,318 | 58,828 | |||||
| Gross margin | 85.2 | % | 82.6 | % | |||
| Operating income | 9,247 | 136 | |||||
| Operating margin | 10.3 | % | 0.2 | % | |||
| Net loss | (71,372 | ) | (40,605 | ) | |||
| Cash flow from operating activities | 10,041 | 12,476 | |||||
| Non-GAAP Financial Data: | |||||||
| Operating income | 15,879 | 5,653 | |||||
| Operating margin | 17.7 | % | 7.9 | % | |||
| Net income | 16,866 | 6,899 | |||||
| Adjusted EBITDA | 17,632 | 7,304 | |||||
| Adjusted EBITDA margin | 19.7 | % | 10.3 | % | |||
| Cellebrite DI Ltd. Condensed Consolidated Balance Sheets (U.S. Dollars in thousands) | |||||||
| March 31, | December 31, | ||||||
| 2024 | 2023 | ||||||
| (Unaudited) | (Audited) | ||||||
| Assets | |||||||
| Current assets | |||||||
| Cash and cash equivalents | $ | 122,432 | $ | 189,517 | |||
| Short-term deposits | 103,669 | 74,713 | |||||
| Marketable securities | 50,453 | 38,693 | |||||
| Trade receivables (net of allowance for doubtful accounts of | |||||||
| March 31, 2024 and December 31, 2023, respectively) | 61,643 | 77,269 | |||||
| Prepaid expenses and other current assets | 25,647 | 26,400 | |||||
| Contract acquisition costs | 4,957 | 5,550 | |||||
| Inventories | 9,259 | 9,940 | |||||
| Total current assets | 378,060 | 422,082 | |||||
| Non-current assets | |||||||
| Other non-current assets | 6,732 | 7,341 | |||||
| Marketable securities | 70,706 | 28,859 | |||||
| Deferred tax assets, net | 7,789 | 7,024 | |||||
| Property and equipment, net | 15,583 | 15,896 | |||||
| Intangible assets, net | 10,417 | 10,594 | |||||
| Goodwill | 26,829 | 26,829 | |||||
| Operating lease right-of-use assets, net | 13,021 | 14,260 | |||||
| Total non-current assets | 151,077 | 110,803 | |||||
| Total assets | $ | 529,137 | $ | 532,885 | |||
| Liabilities and shareholders’ equity | |||||||
| Current Liabilities | |||||||
| Trade payables | $ | 7,045 | $ | 8,282 | |||
| Other accounts payable and accrued expenses | 36,706 | 44,845 | |||||
| Deferred revenues | 186,028 | 195,725 | |||||
| Operating lease liabilities | 4,839 | 4,972 | |||||
| Total current liabilities | 234,618 | 253,824 | |||||
| Long-term liabilities | |||||||
| Other long-term liabilities | 6,126 | 5,515 | |||||
| Deferred revenues | 42,071 | 47,098 | |||||
| Restricted Sponsor Shares liability | 66,132 | 47,247 | |||||
| Price Adjustment Shares liability | 122,082 | 81,715 | |||||
| Warrant liability | 76,704 | 54,117 | |||||
| Operating lease liabilities | 8,110 | 9,157 | |||||
| Total long-term liabilities | 321,225 | 244,849 | |||||
| Total liabilities | $ | 555,843 | $ | 498,673 | |||
| Shareholders’ equity | |||||||
| Share capital | *) | *) | |||||
| Additional paid-in capital | (74,881 | ) | (84,896 | ) | |||
| Treasury share, NIS 0.00001 par value; 41,776 ordinary shares | (85 | ) | (85 | ) | |||
| Accumulated other comprehensive income | 1,489 | 1,050 | |||||
| Retained earnings | 46,771 | 118,143 | |||||
| Total shareholders’ equity | (26,706 | ) | 34,212 | ||||
| Total liabilities and shareholders’ equity | $ | 529,137 | $ | 532,885 | |||
| *) Less than 1 USD | |||||||
| Cellebrite DI Ltd. Condensed Consolidated Statements of Income (Loss) (U.S Dollars in thousands, except share and per share data) | |||||||
| For the three months ended | |||||||
| March 31, | |||||||
| 2024 | 2023 | ||||||
| (Unaudited) | (Unaudited) | ||||||
| Revenue: | |||||||
| Subscription services | $ | 62,103 | $ | 47,367 | |||
| Term-license | 17,119 | 13,915 | |||||
| Total subscription | 79,222 | 61,282 | |||||
| Other non-recurring | 3,568 | 2,918 | |||||
| Professional services | 6,792 | 7,034 | |||||
| Total revenue | 89,582 | 71,234 | |||||
| Cost of revenue: | |||||||
| Subscription services | 5,798 | 4,492 | |||||
| Term-license | — | 2 | |||||
| Total subscription | 5,798 | 4,494 | |||||
| Other non-recurring | 3,094 | 2,981 | |||||
| Professional services | 4,372 | 4,931 | |||||
| Total cost of revenue | 13,264 | 12,406 | |||||
| Gross profit | $ | 76,318 | $ | 58,828 | |||
| Operating expenses: | |||||||
| Research and development | 23,197 | 21,131 | |||||
| Sales and marketing | 32,059 | 27,601 | |||||
| General and administrative | 11,815 | 9,960 | |||||
| Total operating expenses | $ | 67,071 | $ | 58,692 | |||
| Operating income | $ | 9,247 | $ | 136 | |||
| Financial expense, net | (78,576 | ) | (38,775 | ) | |||
| Loss before tax | (69,329 | ) | (38,639 | ) | |||
| Tax expense | 2,043 | 1,966 | |||||
| Net Loss | $ | (71,372 | ) | $ | (40,605 | ) | |
| Loss per share | |||||||
| Basic | $ | (0.36 | ) | $ | (0.21 | ) | |
| Diluted | $ | (0.36 | ) | $ | (0.21 | ) | |
| Weighted average shares outstanding | |||||||
| Basic | 196,823,502 | 186,338,076 | |||||
| Diluted | 196,823,502 | 198,184,236 | |||||
| Other comprehensive income (loss): | |||||||
| Unrealized loss on hedging transactions | (524 | ) | (44 | ) | |||
| Unrealized (loss) income on marketable securities | (220 | ) | 177 | ||||
| Currency translation adjustments | 1,183 | (598 | ) | ||||
| Total other comprehensive income (loss), net of tax | 439 | (465 | ) | ||||
| Total other comprehensive loss | $ | (70,933 | ) | $ | (41,070 | ) | |
| Cellebrite DI Ltd. Condensed Consolidated Statements of Cash Flow (U.S Dollars in thousands, except share and per share data) | |||||||
| For the three months ended | |||||||
| March 31, | |||||||
| 2024 | 2023 | ||||||
| (Unaudited) | (Unaudited) | ||||||
| Cash flow from operating activities: | |||||||
| Net loss | $ | (71,372 | ) | $ | (40,605 | ) | |
| Adjustments to reconcile net loss to net cash provided by operating activities: | |||||||
| Share based compensation | 5,696 | 4,457 | |||||
| Amortization of premium, discount and accrued interest on marketable securities | (547 | ) | (171 | ) | |||
| Depreciation and amortization | 2,680 | 2,447 | |||||
| Interest income from short term deposits | (2,828 | ) | (684 | ) | |||
| Deferred tax assets, net | (626 | ) | 560 | ||||
| Remeasurement of Warrant liability | 22,587 | 9,809 | |||||
| Remeasurement of Restricted Sponsor Shares liability | 18,885 | 11,042 | |||||
| Remeasurement of Price Adjustment Shares liabilities | 40,367 | 19,942 | |||||
| Decrease in trade receivables | 15,258 | 9,627 | |||||
| (Decrease) increase in deferred revenue | (13,406 | ) | 10,468 | ||||
| Decrease (increase) in other non-current assets | 609 | (927 | ) | ||||
| Decrease (increase) in prepaid expenses and other current assets | 1,967 | (3,637 | ) | ||||
| Changes in operating lease assets | 1,328 | 1,367 | |||||
| Changes in operating lease liability | (1,269 | ) | (1,562 | ) | |||
| Decrease (increase) in inventories | 677 | (1,225 | ) | ||||
| (Decrease) Increase in trade payables | (1,142 | ) | 264 | ||||
| Decrease in other accounts payable and accrued expenses | (9,434 | ) | (8,879 | ) | |||
| Increase in other long-term liabilities | 611 | 183 | |||||
| Net cash provided by operating activities | 10,041 | 12,476 | |||||
| Cash flows from investing activities: | |||||||
| Purchases of property and equipment | (1,495 | ) | (1,064 | ) | |||
| Purchase of Intangible assets | (625 | ) | — | ||||
| Investment in marketable securities | (68,392 | ) | (16,352 | ) | |||
| Proceeds from maturity of marketable securities | 15,045 | 16,073 | |||||
| Investment in short term deposits | (43,000 | ) | (16,000 | ) | |||
| Redemption of short-term deposits | 16,872 | 13,279 | |||||
| Net cash used in investing activities | (81,595 | ) | (4,064 | ) | |||
| Cash flows from financing activities: | |||||||
| Exercise of options to shares | 4,319 | 2,106 | |||||
| Proceeds from Employee Share Purchase Plan, net | 750 | 624 | |||||
| Net cash provided by financing activities | 5,069 | 2,730 | |||||
| Net (decrease) increase in cash and cash equivalents | (66,485 | ) | 11,142 | ||||
| Net effect of Currency Translation on cash and cash equivalents | (600 | ) | 185 | ||||
| Cash and cash equivalents at beginning of period | 189,517 | 87,645 | |||||
| Cash and cash equivalents at end of period | $ | 122,432 | $ | 98,972 | |||
| Supplemental cash flow information: | |||||||
| Income taxes paid | $ | 791 | $ | 3,625 | |||
| Non-cash activities | |||||||
| Operating lease liabilities arising from obtaining right of use assets | $ | 89 | $ | 1,030 | |||
| Cellebrite DI Ltd. Reconciliation of GAAP to Non-GAAP Financial Information (U.S Dollars in thousands, except share and per share data) | ||||||
| For the three months ended | ||||||
| March 31, | ||||||
| 2024 | 2023 | |||||
| (Unaudited) | (Unaudited) | |||||
| Cost of revenues | $ | 13,264 | $ | 12,406 | ||
| Less: | ||||||
| Share based compensation | 430 | 386 | ||||
| Acquisition related costs | 2 | 13 | ||||
| Non-GAAP cost of revenues | $ | 12,832 | $ | 12,007 | ||
| For the three months ended | |||||
| March 31, | |||||
| 2023 | 2022 | ||||
| (Unaudited) | (Unaudited) | ||||
| Gross profit | $ | 76,318 | $ | 58,828 | |
| Share based compensation | 430 | 386 | |||
| Acquisition related costs | 2 | 13 | |||
| Non-GAAP gross profit | $ | 76,750 | $ | 59,227 | |
| For the three months ended | |||||
| March 31, | |||||
| 2024 | 2023 | ||||
| (Unaudited) | (Unaudited) | ||||
| Operating expenses | $ | 67,071 | $ | 58,692 | |
| Less: | |||||
| Share based compensation | 5,266 | 4,071 | |||
| Amortization of intangible assets | 927 | 796 | |||
| Acquisition related costs | 7 | 251 | |||
| Non-GAAP operating expenses | $ | 60,871 | $ | 53,574 | |
| For the three months ended | |||||
| March 31, | |||||
| 2024 | 2023 | ||||
| (Unaudited) | (Unaudited) | ||||
| Operating income | $ | 9,247 | $ | 136 | |
| Share based compensation | 5,696 | 4,457 | |||
| Amortization of intangible assets | 927 | 796 | |||
| Acquisition related costs | 9 | 264 | |||
| Non-GAAP operating income | $ | 15,879 | $ | 5,653 | |
| Cellebrite DI Ltd. Reconciliation of GAAP to Non-GAAP Financial Information (U.S Dollars in thousands, except share and per share data) | |||||||
| For the three months ended | |||||||
| March 31, | |||||||
| 2024 | 2023 | ||||||
| (Unaudited) | (Unaudited) | ||||||
| Net loss | $ | (71,372 | ) | $ | (40,605 | ) | |
| Share based compensation | 5,696 | 4,457 | |||||
| Amortization of intangible assets | 927 | 796 | |||||
| Acquisition related costs | 9 | 264 | |||||
| Tax expense, net | (233 | ) | 1,194 | ||||
| Finance expense from financial derivatives | 81,839 | 40,793 | |||||
| Non-GAAP net income | $ | 16,866 | $ | 6,899 | |||
| Non-GAAP Earnings per share: | |||||||
| Basic | $ | 0.08 | $ | 0.04 | |||
| Diluted | $ | 0.08 | $ | 0.03 | |||
| Weighted average shares outstanding: | |||||||
| Basic | 196,823,502 | 186,338,076 | |||||
| Diluted | 211,256,086 | 198,184,236 | |||||
| For the three months ended | |||||||
| March 31, | |||||||
| 2024 | 2023 | ||||||
| (Unaudited) | (Unaudited) | ||||||
| Net loss | $ | (71,372 | ) | $ | (40,605 | ) | |
| Financial expense, net | 78,576 | 38,775 | |||||
| Tax expense | 2,043 | 1,966 | |||||
| Share based compensation | 5,696 | 4,457 | |||||
| Amortization of intangible assets | 927 | 796 | |||||
| Acquisition related costs | 9 | 264 | |||||
| Depreciation expenses | 1,753 | 1,651 | |||||
| Adjusted EBITDA | $ | 17,632 | $ | 7,304 | |||
FAQ
What were Cellebrite's Q1 2024 revenues?
What is Cellebrite's Q1 2024 ARR?
How did Cellebrite's subscription revenue perform in Q1 2024?
What is Cellebrite's Q1 2024 adjusted EBITDA?
What was Cellebrite's GAAP net loss for Q1 2024?
What is Cellebrite's outlook for full-year 2024?
